Chronic Lymphocytic Leukemia Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Birmingham, Alabama
  • +866 more
2022-04-07
Apr 7, 2022
M
Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax
Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
2022-04-07
Apr 7, 2022
N
Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Recruiting
  • Chronic Lymphocytic Leukemia
  • During Venetoclax
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022
A
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
Recruiting
  • Chronic Lymphocytic Leukemia
  • Fountain Valley, California
  • +276 more
2022-04-07
Apr 7, 2022
N
Testing the Effects of Early Treatment With Venetoclax and Obinutuzumab Versus Delayed Treatment With Venetoclax and Obinutuzumab for Newly Diagnosed Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Do Not Have Symptoms, the EVOLVE CLL/SLL Study
Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Obinutuzumab
  • +3 more
  • Birmingham, Alabama
  • +461 more
2022-04-06
Apr 6, 2022
S
Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL - 2020
Terminated
Has Results
  • Chronic Lymphocytic Leukemia
  • +3 more
  • TP-0903
  • TP-0903 and ibrutinib combination therapy
  • Phoenix, Arizona
  • +5 more
2022-04-04
Apr 4, 2022
N
Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Birmingham, Alabama
  • +873 more
2022-04-05
Apr 5, 2022
O
CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies
Recruiting
  • Acute Lymphoblastic Leukemia
  • +2 more
  • CLIC-1901
  • Vancouver, British Columbia, Canada
  • +1 more
2022-03-26
Mar 26, 2022
N
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Active, not recruiting
  • Anemia
  • +2 more
  • Birmingham, Alabama
  • +795 more
2022-04-05
Apr 5, 2022
P
Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens
Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • (no location specified)
2022-04-02
Apr 2, 2022
N
Reduced Intensity Conditioning Transplant Using Haploidentical Donors - 2020
Completed
  • Chronic Myelogenous Leukemia
  • +9 more
  • Atlanta, Georgia
    Northside Hospital
2022-04-04
Apr 4, 2022
A
ALICIA (Acalabrutinib in CLL Therapy)
Recruiting
  • Chronic Lymphocytic Leukemia
    • Irkutsk, Russian Federation
    • +12 more
    2022-03-25
    Mar 25, 2022
    W
    Early Intervention With Acalabrutinib in Patients With High Risk CLL
    Withdrawn
    • Chronic Lymphocytic Leukemia
    • CLL/SLL
    • New York, New York
      Weill Cornell Medicine
    2022-03-25
    Mar 25, 2022
    T
    Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant
    Recruiting
    • Acute Lymphoblastic Leukemia
    • +15 more
    • Hematopoietic Cell Transplantation
    • +7 more
    • Philadelphia, Pennsylvania
      Sidney Kimmel Cancer Center at Thomas Jefferson University
    2022-04-01
    Apr 1, 2022
    U
    Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia
    Recruiting
    • Chronic Lymphocytic Leukemia
    • +4 more
      • Bobigny, France
      • +8 more
      2022-03-23
      Mar 23, 2022
      N
      Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer
      Recruiting
      • Waldenstrom Macroglobulinemia
      • +4 more
        • Bethesda, Maryland
          National Institutes of Health Clinical Center, 9000 Rockville Pi
        2022-03-31
        Mar 31, 2022
        A
        CLL Therapy Approaches in Russia
        Recruiting
        • Chronic Lymphocytic Leukemia
          • Irkutsk, Russian Federation
          • +5 more
          2022-03-30
          Mar 30, 2022
          I
          A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)
          Recruiting
          • Chronic Lymphocytic Leukemia
          • Non Hodgkin Lymphoma
          • Birmingham, Alabama
          • +48 more
          2022-03-30
          Mar 30, 2022
          K
          Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
          Recruiting
          • Diffuse Large B Cell Lymphoma
          • +2 more
          • Goshen, Indiana
          • +39 more
          2022-03-28
          Mar 28, 2022
          I
          Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL
          Not yet recruiting
          • Chronic Lymphocytic Leukemia
          • +2 more
          • Zanubrutinib, Fludarabine, cyclophosphamide and rituximab
          • Zanubrutinib, bendamustine, rituximab
          • Tianjin, Tianjin, China
            Institute of Hematology & Blood Diseases Hospital
          2022-03-18
          Mar 18, 2022
          W
          Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy
          Recruiting
          • Chronic Lymphocytic Leukemia
          • +2 more
          • New York, New York
            Weill Cornell Medicine
          2022-03-29
          Mar 29, 2022
          A
          A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
          Recruiting
          • Chronic Lymphocytic Leukemia
          • +2 more
          • Phoenix, Arizona
          • +30 more
          2022-03-28
          Mar 28, 2022
          M
          Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia
          Active, not recruiting
          • Chronic Lymphocytic Leukemia
          • +5 more
          • Houston, Texas
            M D Anderson Cancer Center
          2022-03-15
          Mar 15, 2022
          B
          ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL
          Recruiting
          • Chronic Lymphocytic Leukemia
          • Small Lymphocytic Lymphoma
          • Bengbu, Anhui, China
          • +55 more
          2022-03-25
          Mar 25, 2022
          U
          Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma
          Withdrawn
          • Acute Lymphoblastic Leukemia
          • +2 more
          • PACE CART19
          • (no location specified)
          2022-03-09
          Mar 9, 2022